AYTU BIOPHARMA, INC Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31)
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AYTU BIOPHARMA, INC development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for the quarter ending 2015-02-28 was $0.00.
- AYTU BIOPHARMA, INC development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for the quarter ending 2014-11-30 was $15.00K, a 400.00% increase year-over-year.
- AYTU BIOPHARMA, INC development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for the quarter ending 2014-05-31 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for the quarter ending 2014-02-28 was $0.00.
- AYTU BIOPHARMA, INC development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for fiscal 2013 was $5.00K, a 72.55% decline from fiscal 2012.
- AYTU BIOPHARMA, INC development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for fiscal 2012 was $18.21K.
| Period end | Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) 3 month | Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) 12 month |
|---|---|---|
| 2015-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-04-15 | |
| 2014-11-30 | $15.00K 10-Q · filed 2015-01-12 | |
| 2014-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-07-10 | $3.00K derived: sum of 4 quarters · filed 2014-11-26 |
| 2014-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-04-11 | $5.30K derived: sum of 4 quarters · filed 2014-11-26 |
| 2013-11-30 | $3.00K 10-Q · filed 2014-01-10 | $3.00K derived: sum of 4 quarters · filed 2014-11-26 |
| 2013-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-26 | $5.00K 10-K · filed 2014-11-26 |
| 2013-05-31 | $2.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-06-28 | |
| 2013-02-28 | -$2.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-04-11 | |
| 2012-11-30 | $5.00K 10-Q · filed 2013-01-14 | |
| 2012-08-31 | $18.21K 10-K · filed 2014-11-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |